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Abstract
Objective:	The	association	between	secundum	atrial	septal	defects	(ASD)	and	asthma‐
like	dyspnea	with	consequent	long‐term	pulmonary	inhalant	use,	is	poorly	understood	
in	adult	ASD	patients.	Airway	hyperresponsiveness	is	suggested	to	be	the	underlying	
mechanism	of	cardiac	asthma	from	mitral	valve	disease	and	ischemic	cardiomyopathy.	
We	hypothesized	that	airway	hyperresponsiveness	may	also	be	found	in	adult	ASD	
patients.	Our	aim	was	to	study	airway	responsiveness	in	adult	ASD	patients	before	
percutaneous	closure	and	at	short‐and	long‐term	postprocedural	follow‐up.
Methods:	This	prospective	study	included	31	ASD	patients	(65%	female,	mean	age	
49	±	15y)	who	underwent	spirometry	and	bronchoprovocation	testing	pre‐and	six‐
month	 postprocedurally,	 with	 additional	 bronchoprovocation	 at	 2‐year	 follow‐up.	
Airway	hyperresponsiveness	was	defined	as	≥20%	fall	of	forced	expiratory	volume	in	
1‐second	(FEV1)	following	<8.0	mg/mL	of	inhaled	methacholine.
Results:	 Airway	 hyperresponsiveness	 was	 found	 in	 19/30	 patients	 (63%[95%CI	
45%‐81%];	post	hoc	statistical	power	=	89%).	Asthma‐like	symptoms	wheezing,	chest	
tightness,	and	cough	were	more	frequently	reported	in	airway	hyperresponsive	pa‐
tients.	Airway	responsiveness	was	not	influenced	by	successful	percutaneous	ASD	
closure,	 corresponding	 to	 persistence	 of	 asthma‐like	 symptoms	 postclosure.	
Regardless	of	airway	responsiveness,	postprocedural	right‐sided	reverse	remodeling	
significantly	improved	dyspnea	and	pulmonary	function.
Conclusions:	This	study	is	the	first	to	report	a	high	prevalence	of	airway	hyperresponsiveness	
in	a	cohort	of	unrepaired	adult	ASD	patients,	and	confirms	the	association	between	asthma‐
like	symptoms	and	ASD	in	adults.	Attention	to	symptoms	and	pulmonary	function	should	be	
given	during	clinical	follow‐up	of	adult	ASD	patients,	both	before	and	long	after	repair.
K E Y W O R D S
adult	congenital	heart	disease,	airway	hyperresponsiveness,	asthma,	atrial,	device	closure,	
dyspnea,	heart	septal	defects
2  |     NASSIF et al.
1  | INTRODUC TION
Secundum	atrial	septal	defects	(ASDs)	are	the	second	most	common	
congenital	heart	defects,	and	may	manifest	late	into	adulthood	with	
symptoms	of	dyspnea	or	palpitations.1	The	association	between	ASD	
and	asthma‐like	dyspnea,	such	as	wheezing	and	chest	tightness,	 is	
commonly	acknowledged	in	the	pediatric	community,2	yet	unequally	
established	in	adult	cardiology.	The	prevalence	of	asthma‐like	symp‐
toms	and	pulmonary	inhalant	use	in	an	adult	ASD	study	cohort	has	
recently	been	suggested	in	a	questionnaire‐based	study	of	80	adult	
ASD	patients	in	which	one‐third	of	patients	reported	wheezing	and	
chest	 tightness	 and	 20%	 used	 bronchodilators.3	 Also,	 in	 a	 multi‐
center	population‐based	study	(unpublished	data),	use	of	pulmonary	
inhalants	was	found	to	be	twice	as	high	in	adult	ASD	patients	com‐
pared	 to	 the	general	population,	both	before	and	 long	after	shunt	
repair.	As	of	now,	however,	 the	possible	underlying	mechanism	of	
asthma‐like	dyspnea	with	consequent	long‐term	pulmonary	inhalant	
use	in	adult	ASD	patients	still	remains	unclear.
Among	 cardiac	 diseases,	 asthma‐like	 symptoms	 known	 as	 “car‐
diac	asthma”	are	extensively	described	in	patients	with	chronic	heart	
failure	with	or	without	mitral	 valve	disease,4‐9	 and	airway	hyperre‐
sponsiveness	 has	 been	 suggested	 to	 be	 the	 underlying	mechanism	
of	these	symptoms.	Airway	hyperresponsiveness	is	characterized	by	
more	sensitive	and	increased	airway	narrowing	to	nonspecific	stimuli	
that	normally	 lead	to	 little	or	no	airway	response.10	Unlike	 in	bron‐
chial	asthma,	airway	hyperresponsiveness	can	exist	without	a	(family)	
history	of	atopy	like	allergic	rhinitis	or	atopic	eczema,	or	evidence	of	
eosinophilic	airways	inflammation.11	Since	ASD	patients	may	present	
with	asthma‐like	dyspnea,	we	hypothesized	that	airway	hyperrespon‐
siveness	may	also	be	found	in	adult	ASD	patients.	Hence,	our	aim	was	
to	study	airway	responsiveness	in	adult	ASD	patients	before	percuta‐
neous	closure	and	at	short‐and	long‐term	postprocedural	follow‐ups.
2  | METHODS
2.1 | Study design
In	 this	 prospective	observational	 study,	we	evaluated	 consecutive	
adult	patients	with	 secundum	ASD	referred	 for	percutaneous	clo‐
sure	in	the	Center	for	Congenital	Heart	Disease	Amsterdam	Leiden	
within	a	period	of	13	months	(2014‐2015).	Indication	for	ASD	closure	
was	decided	by	our	Grown‐Up	Congenital	Heart	team	based	on	cur‐
rent	guidelines.12	Pulmonary	function	testing	and	echocardiographic	
imaging	were	performed	pre‐	and	at	six‐month	postprocedural	fol‐
low‐up	as	routine	clinical	work‐up.	Pulmonary	function	testing	was	
repeated	at	2‐year	postprocedural	 follow‐up	as	part	of	 this	 study.	
Additional	 cardiovascular	 magnetic	 resonance	 (CMR)	 imaging	was	
performed	at	the	physician’s	discretion.	The	study	cohort	comprised	
patients	 who	 had	 complete	 baseline	 pulmonary	 testing	 and	 who	
underwent	 successful	 percutaneous	ASD	 closure.	 This	 study	 con‐
forms	to	the	1975	Declaration	of	Helsinki	and	all	patients	provided	
informed	consent	according	to	local	medical	ethical	regulations.
2.2 | ASD closure
Percutaneous	ASD	closure	was	performed	conform	current	guide‐
lines12	 and	 under	 general	 anesthesia	 for	 transesophageal	 echo‐
cardiographic	 guidance	 of	 device	 placement.	 Routinely,	 heparin	
and	 aspirin	 were	 administered	 at	 the	 start	 of	 the	 procedure	 and	
an	 Amplatzer	 Septal	 Occluder	 (Abbott	 Vascular	 BV,	 Santa	 Clara,	
California)	of	appropriate	size	was	 implanted.	Postprocedural	ther‐
apy	 included	 a	 6‐month	 dual	 antiplatelet	 regimen	 of	 daily	 aspirin	
100	mg	and	clopidogrel	75	mg	after	a	600‐mg	loading	dose.
2.3 | Methacholine challenge testing
Standardized	 spirometry	was	 performed	 on	 a	MasterScreen	 PFT	
(Jaeger,	 Wurzburg,	 Germany)	 and	 predicted	 values	 were	 based	
on	 age,	 sex,	 and	 height.13	 Bronchoprovocation	 testing	 was	 per‐
formed	according	to	the	2‐minute	tidal	breathing	method10,14	using	
a	 MasterScreen	 Body	 plethysmograph	 (Jaeger).	 Changes	 in	 air‐
way	caliber	were	expressed	as	forced	expiratory	volume	in	1	sec‐
ond	 (FEV1).	 After	 inhaling	 0.9%	 isotonic	 saline,	 patients	 received	
doubling	 doses	 of	methacholine	 chloride	 from	 0.6	 to	 1.2	mg/mL	
until	FEV1 decreased	≥20%	from	baseline	or	when	a	maximum	of	
19.6	mg/mL	methacholine	was	administered.	Airway	hyperrespon‐
siveness	was	defined	as	≥20%	of	FEV1 decline	 from	baseline	 fol‐
lowing	≤8.0	mg/mL	of	inhaled	methacholine.15	The	dose‐response	
curve	 served	 as	 quantitative	 index	 of	 airway	 responsiveness	 to	
visualize	 potential	 changes	 from	 the	 hyperresponsive	 patients	
toward	the	normal	 range	of	all	patients.	A	2‐point	dose‐response	
slope	 (DRS)	was	calculated	as	the	percentage	FEV1 decline	at	the	
last	methacholine	concentration,	divided	by	the	cumulative	metha‐
choline	dose	administered.16
As	 per	 clinical	 protocol,	 patients	 were	 excluded	 from	 bron‐
choprovocation	 testing	 if	 they	 had	 a	 myocardial	 infarction	
<3	months,	chronic	heart	disease	or	epilepsy	with	medical	therapy,	
were	 pregnant	 or	 breast‐feeding,	 or	 had	 FEV1 <70%	 of	 predicted.	
Patients	 were	 instructed	 not	 to	 smoke	 <2	h	 prior	 to	 testing,	 use	
short‐acting	ß2‐agonist	<8	h,	anticholinergic	inhaler/antileukotrienes	
<24	h,	 long‐acting	ß2‐agonist,	or	combination	with	 inhaled	cortico‐
steroids/theophyllines/antihistamines/chromones	 <48	h,	 long‐act‐
ing	 antimuscarinics	 <4	days,	 and	 the	 test	 was	 postponed	 in	 case	
of	respiratory	tract	 infections	<3	weeks.	To	minimize	confounding,	
postprocedural	 bronchoprovocation	 testing	 was	 kept	 identical	 to	
baseline	in	terms	of	diluent	steps	and	the	hour	of	the	day	on	which	
the	test	was	performed.
2.4 | Questionnaire
The	 validated	 Dutch	 version	 of	 the	 European	 Community	
Respiratory	 Health	 Survey	 (ECRHS)	 was	 conducted	 before	 any	
spirometry,	enquiring	about	symptoms	of	wheezing	not	associated	
with	 the	 flu,	 (nocturnal)	 chest	 tightness,	 resting/exercise/noc‐
turnal	 dyspnea,	 (nocturnal)	 cough,	 and/or	 phlegm	 during	winter,	
troubled	 breathing,	 diagnosed	 asthma,	 nasal	 allergies,	 hay	 fever,	
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and	 eczema.17	 All	 questions	 refer	 to	 symptoms	 in	 the	 previous	
12	months	 or	 6	months,	 at	 baseline	 and	 follow‐up,	 respectively.	
Asthma	 definition	 and	 classification	 were	 based	 on	 the	 Global	
Initiative	for	Asthma	guidelines.11
2.5 | Imaging
Two‐dimensional	 echocardiography	 and	 CMR	 were	 performed	
at	 baseline	 and	 6‐month	 follow‐up	 as	 part	 of	 the	 outpatient	 vis‐
its.	 Echocardiographic	 views	 were	 acquired	 on	 a	 Vivid	 9	 (GE	
Healthcare,	 Horten,	 Norway)	 based	 on	 recommendations	 of	 the	
American	 Society	 of	 Echocardiography	 and	 European	 Association	
of	Cardiovascular	 Imaging18	and	were	analyzed	offline.	Right	atrial	
size	was	measured	in	the	dedicated	apical	4‐chamber	view	by	single‐
plane	area	measurements,	and	right	systolic	function	was	assessed	
by	the	velocity	of	the	tricuspid	annular	systolic	motion.	Right	ven‐
tricular	single‐plane	and	 left	atrial	and	ventricular	biplane	volumes	
and	left	ejection	fraction	were	measured	using	the	disk	summation	
technique.	Postprocedural	pulmonary	capillary	wedge	pressure	was	
estimated	by	the	E/eʹ	ratio	as	formulated	by	Nagueh	et	al.19
CMR	images	were	acquired	on	a	clinical	1.5	or	3.0	Tesla	scanner	
(Siemens,	Erlangen,	Germany	or	Philips,	Best,	The	Netherlands)	with	
a	 phased‐array	 cardiac	 receiver	 coil.	 Functional	 imaging	 was	 per‐
formed	using	retrospectively	electrocardiographically	gated	steady‐
state	free	precession	cine	imaging	with	breath	holding.	Contiguous	
short‐axis	 slices	 were	 acquired,	 covering	 the	 entire	 left	 and	 right	
ventricle	from	base	to	apex,	to	examine	global	ventricular	function	
(typical	 scan	 parameters:	 slice	 thickness	 6	mm	with	 interslice	 gap	
3	mm,	matrix	 192	 x	 192,	 temporal	 resolution	 30‐55	ms,	 flip	 angle	
75°).	Analyses	of	right‐	and	left‐sided	end‐diastolic	and	end‐systolic	
volumes	 were	 done	 by	 manual	 endocardial	 contouring	 (excluding	
papillary	muscles	and	trabeculae)	on	short‐axis	frames	from	which	
ejection	fraction	was	also	derived.	Analysis	was	performed	offline	
with	dedicated	software	(MASS	v.5.1	2015‐EXP	beta;	Medis,	Leiden,	
The	Netherlands)	by	an	experienced	imaging	cardiologist	(AH)	who	
was	blinded	to	all	patient	characteristics	and	outcome	measures.
2.6 | Statistical analysis
Baseline	 characteristics,	 hemodynamics,	 and	 pulmonary	 function	
parameters	 are	 presented	 as	 mean	 ±standard	 deviation,	 median	
[25th‐75th	percentile],	or	frequency	(percentage)	according	to	distri‐
bution.	Paired	pre‐	and	postprocedural	variables	were	tested	using	
the	two‐tailed	paired	t	test,	Wilcoxon	signed‐rank	test,	or	McNemar’s	
test	 where	 appropriate.	 The	 Friedman	 test	 was	 used	 to	 compare	
dose‐response	slopes	at	pre‐	and	6‐month	and	2‐year	post‐proce‐
dural	follow‐ups.	Differences	between	hyper‐and	normoresponsive	
patients	were	 tested	using	 the	Mann‐Whitney	U	or	Fisher’s	 exact	
test.	Correlations	were	linearly	tested	unless	mentioned	otherwise.	
A	two‐sided	P value	<.05	was	considered	statistically	significant.	All	
analyses	were	performed	using	 IBM	SPSS	Statistics	 for	Windows,	
Version	23	(IBM	Corp.,	Armonk,	New	York).
The	primary	outcome	of	this	study	was	airway	hyperresponsive‐
ness	at	baseline	before	ASD	closure.	Secondary	outcomes	 include	
airway	 responsiveness	 at	 6‐month	 and	 2‐year	 postprocedural	 fol‐
low‐up,	 and	 ventilatory	 and	 hemodynamic	 changes	 from	 baseline	
to	6	months	after	percutaneous	ASD	closure.	This	hypothesis‐gen‐
erating	study	did	not	allow	for	sample	size	specification.	Instead,	a	
post	 hoc	 power	 analysis	 was	 conducted	 using	 G*Power	 software	
(Heinrich‐Heine‐Universität	 Düsseldorf,	 Düsseldorf,	 Germany)	 set	
at	alpha	error	0.05	(one‐sided)	and	a	35%	prevalence	of	airway	hy‐
perresponsiveness	in	the	general	population.	A	power	of	≥80%	was	
considered	 a	 significant	 statistical	 power	 for	 the	 reported	 preva‐
lence	of	airway	hyperresponsiveness	in	this	study.
3  | RESULTS
3.1 | Study cohort
Following	the	Grown‐Up	Congenital	Heart	team	decision,	41	adults	
were	consecutively	planned	for	percutaneous	ASD	closure	in	a	13‐
month	period.	Ten	patients	had	incomplete	baseline	pulmonary	as‐
sessment,	therefore	31	ASD	patients	with	complete	preprocedural	
spirometry	 and	 bronchoprovocation	 testing	 formed	 the	 study	 co‐
hort	(Figure	S1).
Baseline	 characteristics	 are	 shown	 in	 Table	 1.	 The	 mean	 age	
was	 49	±	15	years,	 65%	were	 female,	 and	 84%	were	 repaired	 for	
right	ventricular	dilatation	with	a	pulmonary‐to‐systemic‐flow	ratio	
of	 1.9	±	0.9.	 Based	 on	 the	Global	 Initiative	 for	 Asthma	 guidelines,	
4(13%)	patients	had	diagnosed	asthma	(n	=	2	mild,	n	=	2	moderate)	
and	11(35%)	patients	 had	 a	 self‐reported	history	of	 either	 allergic	
rhinitis,	 atopic	 eczema,	 or	 insect	 allergy.	 Ten	 (32%)	 patients	 had	
symptoms	of	wheezing,	chest	tightness,	and/or	nocturnal	dyspnea.	
An	episode	of	resting	dyspnea	was	present	in	21	(68%)	patients,	and	
exertional	dyspnea	was	reported	by	22	(71%)	patients.	Four	patients	
were	 on	 current	 respiratory	medicine	 (n	=	3	 corticosteroids,	 n	=	1	
short‐acting	ß2‐agonist)	and	another	two	used	low‐dose	oral	gluco‐
corticoids	for	comorbidity.
3.2 | Airway responsiveness
Of	the	30	patients	with	bronchoprovocation	testing	(n	=	1	excluded	
for	FEV1 <70%),	19	patients	had	airway	hyperresponsiveness,	 cor‐
responding	to	a	prevalence	of	63%	(95%CI	45%‐81%)	 in	this	study	
population.	 This	 yielded	 a	 post	 hoc	 statistical	 power	 of	 89%.	 The	
dose‐response	curve	of	all	individual	patients	is	shown	in	Figure	1A.
Figure	 1B	 shows	 the	 dose‐response	 slope	 at	 baseline	 and	 at	
6‐month	 and	 2‐year	 postprocedural	 follow‐up.	 At	 baseline,	 the	
hyperresponsive	 patients	 featured	 a	 dose‐response	 slope	 of	 2.87	
[1.34‐3.74]	compared	to	a	slope	of	0.25	 [0.18‐0.32]	 in	 the	11	nor‐
moresponsive	patients	(P	<	.001).	Both	in	hyperresponsive	and	nor‐
moresponsive	patients	the	dose‐response	slopes	at	post‐procedural	
follow‐up	remained	unchanged	from	baseline	(P	=	.75	and	P	=	.42,	re‐
spectively).	Patient	symptoms	before	and	6	months	after	closure	are	
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shown	in	Figure	2.	Numerical	differences	between	hyperresponsive	
and	normoresponsive	patients	were	observed	for	wheezing	(6	[32%]	
vs.	1	[9%]),	cough	(5	[26%]	vs.	1	[9%]),	ever	used	respiratory	medicine	
(6	[32%]	vs.	1	 [9%])	and	the	combination	of	asthma‐like	symptoms	
(8	 [42%]	vs.	1	 [9%];	P	=	.07).	 Irrespective	of	responsiveness	status,	
significant	 postprocedural	 improvement	was	 seen	 in	 symptoms	of	
troubled	 breathing	 and	 exertional	 dyspnea	 (both	 P	<	.001),	 while	
wheezing	and	chest	tightness	reduced	only	slightly	(Figure	2).
3.3 | Effect of closure
Table	 2	 shows	 the	 paired	 ventilatory	 and	 hemodynamic	 changes	
from	baseline	to	6‐month	postprocedural	follow‐up	(mean	follow‐up	
6.0	±	1.0	months),	as	measured	by	spirometry	and	cardiac	 imaging,	
respectively.
At	 baseline	 spirometry,	 FEV1 was	 3.0	±	0.9L/s	 (98%	±	15%	
predicted)	 with	 a	 FEV1/forced	 vital	 capacity	 index	 of	 0.8	±	0.07	
(99%	±	7.8%	predicted).	FEV1 was	associated	with	baseline	symptoms	
of	wheezing	(r2=0.22;	P	=	.008).	Postprocedural	improvements	in	spi‐
rometry	were	seen	most	notably	in	FEV1	(98%	±	15%‐101%	±	14%;	
P	=	.04),	 forced	 vital	 capacity	 (103%	±	16%‐108%	±	15%;	 P	<	.001)	
and	 inspiratory	 vital	 capacity	 (100%	±	16%‐103%	±	15%;	 P	=	.03).	
Low	baseline	 spirometry	values	were	associated	with	baseline	ex‐
ertional	dyspnea	(P	<	.01)	and	its	postprocedural	resolution	(P	≤	.01).
Following	 successful	 percutaneous	 closure,	 significant	 right	
atrial	and	ventricular	reverse	remodeling	was	observed.	CMR‐based	
right	ventricular	end‐diastolic	volume	decreased	from	134	±	40	mL/
m2‐96	±	23	mL/m2	 (P	<	.001),	 corresponding	 to	 right	 ventricular	
stroke	 volume	 reduction	 (r2=0.68;	 P	<	.001).	 Systolic	 pulmonary	
artery	pressure	decline	correlated	with	reduction	in	both	right	atrial	
(r2=0.56;	P	<	.001)	and	ventricular	size	(r2=0.47;	P	=	.002).	Right	ven‐
tricular	end‐diastolic	volume	reduction	was	associated	with	resolu‐
tion	of	troubled	breathing	(r2=0.31;	P	=	.01)	and	exertional	dyspnea	
(r2=0.24;	P	=	.03),	as	well	as	improvement	in	FEV1	(r
2=0.24;	P	=	.03),	
forced	vital	capacity	(r2=0.37;	P	=	.004)	and	inspiratory	vital	capacity	
(r2=0.39;	P	=	.004).
4  | DISCUSSION
This	 study	 is	 the	 first	 to	 report	 a	 high	 prevalence	 of	 airway	 hy‐
perresponsiveness	 in	 a	 cohort	 of	 unrepaired	 adult	 ASD	 patients.	
Asthma‐like	 symptoms	 were	 more	 frequently	 reported	 in	 airway	
hyperresponsive	patients.	Parallel	to	the	unchanged	airway	respon‐
siveness	 after	 successful	 percutaneous	 ASD	 closure,	 asthma‐like	
symptoms	did	not	significantly	 improve	postclosure.	Regardless	of	
airway	 responsiveness,	 postprocedural	 right‐sided	 reverse	 remod‐
eling	significantly	improved	dyspnea	and	pulmonary	function.
4.1 | Airway hyperresponsiveness
Increased	airway	 responsiveness	 to	nonspecific	 stimuli	 is	one	of	
the	major	defining	features	of	asthma,	but	not	pathognomonic	for	
it.11	 In	the	general	adult	population	the	prevalence	of	airway	re‐
sponsiveness	 is	 10%‐16%	 (max.	 25%‐35%	as	 defined	by	 a	≤	10%	
FEV1	decline),
20,21	and	its	risk	factors	include	age,	female	gender,	
atopic	 constitution,	 respiratory	 tract	 infection,	 current	 smok‐
ing,	 and	 genetic	 predisposition.22	 The	 63%	 (95%CI	 45%‐81%)	
F I G U R E  1  Airway	hyperresponsiveness	in	adult	secundum	ASD	patients.	(A)	Per	patient	baseline	dose‐response	curve	of	percentage	
FEV1	decline	in	response	to	the	cumulative	inhaled	methacholine	dose	(n	=	30).	Airway	hyperresponsiveness	was	defined	as	≥20%	FEV1 
reduction	from	baseline	following	≤8.0	mg/mL	of	methacholine.	(B)	Paired	per	patient	methacholine	dose‐response	slopes	at	baseline	and	at	
6‐month	(n	=	28)	and	2‐year	(n	=	22)	postprocedural	follow‐ups.	Abbreviations:	FEV1=	forced	expiratory	volume	in	1	s;	MCh=methacholine.
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prevalence	of	airway	hyperresponsiveness	in	this	study	is	signifi‐
cantly	 higher	 than	 expected	 from	 the	 prevalence	 in	 the	 general	
population	and	cannot	be	accounted	for	by	conventional	risk	fac‐
tors	 of	 hyperresponsiveness.	Only	 a	 few	 patients	 in	 this	 cohort	
were	current	smokers,	and	the	testing	season	had	no	influence	on	
airway	 responsiveness.	None	of	 the	 patients	 had	 comorbid	 lung	
disease	 or	 recent	 pulmonary	 infection	 during	 bronchoprovoca‐
tion.	Patients’	concomitant	medication	excluded	responsiveness‐
affecting	ones	such	as	ACE‐inhibitors,	beta‐blockers	or	diuretics	
to	influence	results.	Although	aspirin	can	incidentally	exacerbate	
respiratory	 disease,23	 no	 evidence	of	 such	medical	 reaction	was	
observed.
Neither	 airway	 reactivity	 (dose‐response	 slope)	 nor	 airway	
sensitivity	 (estimated	by	 the	methacholine	concentration	at	which	
FEV1	decreases	≥20%)	improved	at	six‐month	or	two‐year	follow‐up	
after	successful	ASD	closure.	Our	data	are	consistent	with	studies	
reporting	 unchanged	 airway	 hyperresponsiveness	 after	 treatment	
for	mitral	valve	disease,24‐26	although	some	improvement	in	airway	
sensitivity	was	seen.	A	previous	study	in	acute	on	chronic	heart	fail‐
ure	 patients	 also	 showed	 no	 alteration	 in	 responsiveness	 despite	
adequate	 diuretic	 therapy	 and	 significant	 radiological	 improve‐
ment.27	 Thus,	 pathophysiology	 inherent	 to	 such	 cardiac	 diseases	
seems	 to	 maintain	 airway	 hyperresponsiveness	 despite	 adequate	
therapy,	suggesting	that	flow‐mediated	pulmonary	vascular	disten‐
tion	in	ASD	patients	may	be	a	trigger	rather	than	a	cause	of	airway	
hyperresponsiveness.
4.2 | Asthma‐like symptoms
The	Global	Initiative	for	Asthma	guideline	defines	asthma	by	respira‐
tory	symptoms	such	as	wheezing,	chest	tightness,	cough	and	shortness	
of	breath	that	vary	in	duration	and	intensity,	accompanied	by	variable	
airflow	limitation.11	 In	the	present	study,	wheezing,	chest	tightness,	
and	cough	were	indeed	predominantly	reported	by	hyperresponsive	
ASD	patients,	and	parallel	 to	the	unchanged	airway	responsiveness	
postclosure,	these	asthma‐like	symptoms	did	not	significantly	resolve	
after	 shunt	 repair	 (Figure	2).	Therefore,	 the	present	 study	confirms	
the	association	between	secundum	ASD	and	asthma‐like	symptoms,	
TA B L E  1  Baseline	characteristics	of	the	study	cohort
Total 
N = 31
Demographics
Age,	y 49	±	15
Female 20	(65)
Body	mass	index,	kg/m2 25	±	4.3
Current	smoker 4	(13)
Former	smoker 10	(32)
Pack	years 3.2	[0.7‐23]
Clinical	history
Asthma 4	(13)
Atopic	constitutiona 11	(36)
Atrial	arrhythmia 5	(16)
Symptoms
Asthma‐like	symptomsb 10	(32)
NYHA	class	≥II 22	(71)
Respiratory	medication
Current 4	(13)
Bronchodilators	only 1
Corticosteroids	added 3
Former 4	(13)
Bronchodilators	only 3
Corticosteroids	added 1
ASD	closure	indication
Right	ventricular	dilatation 26	(84)
Paradoxical	embolism 5	(16)
ASD‐related	characteristics
Max.	defect	size,	mm 20	±	6.4
Pulmonary‐to‐systemic‐flow	ratio 1.9	±	0.9
Systolic	pulmonary	artery	pressure,	mmHg 34	±	7.8
Left	atrial	pressure,	mm	Hgc 10	±	2.6
Data	are	presented	as	mean	±SD,	frequencies	(%),	or	median	[25th‐75th	
percentile].	Abbreviation:	NYHA=New	York	Heart	Association.
a≥1	of	the	following:	allergic	rhinitis,	atopic	eczema,	or	insect	allergy.	
b≥1	of	the	following:	“wheezing	without	cold,”	“nocturnal	dyspnea,”	“ever	
diagnosed	with	asthma.”	
cDirect	periprocedural	measurement	during	general	anesthesia	(n	=	24).	
F I G U R E  2  Symptoms	before	and	after	ASD	closure	in	
hyperresponsive	and	normoresponsive	patients.	European	
Community	Respiratory	Health	Survey‐reported	symptoms	at	
baseline	and	6‐month	follow‐up	(n	=	29).	Patients	with	asthma‐like	
symptoms	were	more	likely	airway	hyperresponsive.	The	extent	of	
postprocedural	symptom	relief	was	similar	in	hyperresponsive	and	
normoresponsive	ASD	patients.
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and	additionally	provides	data	that	suggests	that	airway	hyperrespon‐
siveness	is	one	of	the	possible	underlying	mechanisms.
4.3 | Effects of ASD closure
The	most	frequently	reported	symptoms	in	this	study	cohort	were	
troubled	breathing	and	exertional	dyspnea	which,	regardless	of	air‐
way	responsiveness,	resolved	significantly	after	successful	closure.	
The	corresponding	improvement	in	FEV1	and	forced	and	inspiratory	
vital	 capacity	 significantly	 correlated	 with	 reverse	 right	 heart	 re‐
modeling	and	systolic	pulmonary	artery	pressure	decline	at	6‐month	
follow‐up.	With	or	without	the	presence	of	pulmonary	hypertension,	
left‐to‐right	shunts	are	known	to	 increase	pulmonary	apical	perfu‐
sion	 by	 capillary	 recruitment.28	 Indeed,	 the	 observed	 significant	
reverse	 remodeling	 after	 percutaneous	 closure	 may	 suggest	 that	
spatial	 reduction	 in	pulmonary	vascular	volume	and	peripheral	air‐
way	caliber	improves	vital	capacity.29
4.4 | Clinical implications
The	 present	 study	 reports	 a	 high	 prevalence	 of	 airway	 hyperre‐
sponsiveness	 in	a	cohort	of	adult	ASD	patients,	and	proposes	air‐
way	hyperresponsiveness	as	a	possible	mechanism	for	asthma‐like	
symptoms	that	potentially	require	pulmonary	inhalant	use,	both	be‐
fore	and	long	after	closure.	Characteristic	nonspecific	triggers	for	
bronchospasm	such	as	cold	or	dry	air,	abrupt	temperature	changes,	
smoke,	 and	 exercise	 may	 induce	 asthma‐like	 symptoms	 in	 ASD	
patients,	 regardless	of	 repair	status.	Unlike	 in	bronchial	asthma,11 
ASD‐associated	asthma‐like	symptoms	are	not	necessarily	episodic	
over	merely	few	hours	to	days,	but	can	manifest	with	progressive	
TA B L E  2  Ventilatory	and	hemodynamic	parameters	before	and	6	months	after	successful	ASD	closure
n Baseline Follow‐up Δ P value
Spirometry
Forced	expiratory	volume	in	1	s,	%pred 29 98	±	16 101	±	14 2.3	±	6.1 0.05
Forced	vital	capacity,	%pred 29 103	±	16 108	±	15 5.1	±	6.7 <0.001
FEV1/FVC	ratio,	%pred 29 100	±	8 98	±	9 −2.1	±	4.8 0.02
Peak	expiratory	flow,	%pred 29 105	±	22 108	±	21 2.9	±	11 0.15
Max.	expiratory	flow	at	50%	of	expiration,	
%pred
29 83	±	25 78	±	27 −4.3	±	16 0.16
Inspiratory	vital	capacity,	%pred 29 100	±	16 103	±	15 3.3	±	7.5 0.03
Maximal	vital	capacity,	%pred 29 101	±	16 106	±	14 4.6	±	7.1 0.002
Echocardiography
RA	end‐systolic	area,	cm2/m2 27 25	±	9.8 18	±	4.8 −7.0	±	7.6 <0.001
Tricuspid	annular	systolic	motion	velocity,	
cm/s
9 14	±	2.7 12	±	1.7 −1.3	±	2.2 0.11
Systolic	pulmonary	artery	pressure,	mm	Hg 23 34	±	7.8 27	±	4.5 −6.8	±	8.6 0.001
Pulmonary	capillary	wedge	pressure,	mm	Hg 25 n/a 13	±	2.7 n/a n/a
LA	end‐systolic	volume,	ml/m2 24 35	±	14 35	±	9.6 0.9	±	13 0.74
Cardiac	magnetic	resonance
RV	end‐diastolic	volume,	ml 21 249	±	83 182	±	62 −67	±	51 <0.001
RV	end‐diastolic	volume,	ml/m2 21 134	±	40 96	±	23 −38	±	30 <0.001
RV	end‐systolic	volume,	ml 21 104	±	41 83	±	34 −21	±	26 0.001
RV	end‐systolic	volume,	ml/m2 21 56	±	21 44	±	14 −13	±	16 0.002
RV	stroke	volume,	ml 21 145	±	47 101	±	30 −44	±	30 <0.001
RV	ejection	fraction,	% 21 59	±	6.1 56	±	5.6 −3.0	±	3.8 0.002
LV	end‐diastolic	volume,	mls 21 129	±	40 147	±	45 18	±	14 <0.001
LV	end‐diastolic	volume,	ml/m2 21 69	±	16 78	±	19 9.3	±	6.9 <0.001
LV	end‐systolic	volume,	ml 21 45	±	16 52	±	22 6.5	±	9.3 0.005
LV	end‐systolic	volume,	ml/m2 21 24	±	8 27	±	10 3.1	±	4.9 0.009
LV	stroke	volume,	ml 21 84	±	26 96	±	26 12	±	10 <0.001
LV	ejection	fraction,	% 21 65	±	5.5 66	±	6.5 0.4	±	5.3 0.72
LV	cardiac	output,	L/min 21 5.9	±	2.2 6.2	±	1.9 0.3	±	1.0 0.20
Data	are	presented	as	mean	±SD.	Abbreviations:	%Pred,	percentage	of	predicted	value;	FEV1,	forced	expiratory	volume	in	1	s;	FVC,	forced	vital	capac‐
ity;	RA,	right	atrial;	RV,	right	ventricular;	LA,	left	atrial;	LV,	left	ventricular.
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dyspnea	over	the	course	of	months.	Also	unlike	bronchial	asthma,	
these	symptoms	can	manifest	later	in	adult	life,	without	a	positive	
(family)	history	of	asthma	and	atopy.	Such	better	understanding	of	
ASD‐associated	dyspnea	may	potentially	prevent	therapeutic	delay	
of	unrepaired	ASD	with	the	risk	of	complications	from	long‐stand‐
ing	right	ventricular	volume	overload,1	as	well	as	diagnostic	delay	of	
long‐term	postrepair	pulmonary	function	impairment.30
4.5 | Study strengths and limitations
Percutaneous	ASD	closure	provides	a	unique	model	to	validate	the	
assumption	that	observed	pulmonary	function	changes	at	follow‐up	
can	be	fully	attributed	to	left‐to‐right	shunt	closure,	unlike	surgical	
closure	which	can	 influence	pulmonary	 function	by	 the	cardiopul‐
monary	bypass	and	surgical	scar.31	Consequently,	no	control	group	
was	provided	since	patients	had	paired	testing	and	their	postproce‐
dural	state	was	considered	similar	to	controls.	Also,	postprocedural	
bronchoprovocation	testing	was	performed	up	to	2	years	after	ASD	
closure,	allowing	for	observation	of	potential	 long‐term	changes	in	
airway	responsiveness.
Although	 the	 primary	 study	 outcome	was	 supported	 by	 suffi‐
cient	post	hoc	statistical	power,	this	study	included	a	small	number	
of	adult	ASD	patients.	Analyses	of	possible	predictors	of	airway	hy‐
perresponsiveness	were	therefore	beyond	the	scope	of	this	study.	
Symptom	reporting	bias	may	have	been	present,	though	question‐
naires	were	conducted	before	spirometry	and	were	double‐blinded	
of	baseline	questionnaire	answers.	Future	studies	should	continue	
to	investigate	the	possible	underlying	mechanisms	of	persistent	pul‐
monary	symptoms	that	require	pulmonary	inhalants	after	closure,	as	
well	as	elucidate	the	mechanisms	of	coexisting	airway	hyperrespon‐
siveness	in	ASD	patients.
5  | CONCLUSIONS
This	 is	 the	 first	 study	 to	 show	an	 association	between	 secundum	
ASD	and	airway	hyperresponsiveness,	and	confirms	the	association	
between	asthma‐like	symptoms	and	ASD	 in	adults.	Parallel	 to	un‐
changed	airway	responsiveness	after	successful	percutaneous	ASD	
closure,	asthma‐like	symptoms	may	persist	after	repair.	Regardless	
of	airway	responsiveness,	ASD	closure	reduces	general	dyspnea	by	
benefitting	right‐sided	hemodynamics	and	spirometry.	Attention	to	
symptoms	and	pulmonary	 function	should	be	given	during	clinical	
follow‐up	of	adult	ASD	patients,	both	before	and	long	after	repair.
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